Who are we?

Pathcal was founded by researchers and providers at the Hassanpour Lab - Geisel School of Medicine and Dartmouth Health. Our team is dedicated to leveraging the power of deep learning to modernize cancer diagnostics, helping to realize the promises of preventative, value-based care.

In addressing the pathologist shortage and rising cancer rates, we are at the forefront of revolutionizing the industry. With federal support and a focus on democratizing state-of-the-art care, Pathcal develops AI tools to ease clinician burden and advance patient outcomes.

Our journey

July 2017

Algorithm development

Designed and developed an automatic image analysis framework to accurately classify different types of colorectal polyps on WSIs. Intended to assist pathologists with the screening and risk assessment of colorectal cancer.

We presented our work at the Pathology Informatics Summit in Pittsburgh in May 2018 and received the Journal of Pathology Informatics Most Popular Article Award.

April 2020

Large multi-center validation

Expert pathologists validated our AI solution on external data from the Vitamin D/Calcium Polyp Prevention Study (VCPPS), a randomized, multi-center, placebo-controlled chemo-prevention trial at 11 geographically diverse centers across the U.S., to demonstrate product generalizability.

November 2021

Cross-over clinical trial

Completed a prospective validation study to establish our product in a clinical setting and determine if an AI-augmented digital system improves pathologists' classification accuracy compared with a standard microscope assessment.

This study recruited 15 pathologists at different training levels across New Hampshire. When interpreting 100 slides, the performance of the pathologist cohort significantly improved when using our tool, proving the effectiveness of AI/ML integration with the current clinical workflow.

September 2022

Patent publication

Invented a novel AI/ML model (SaMD) for cancer diagnostics with federal support under grants from the National Institutes of Health (NIH); received a utility patent for the system.

December 2022 - March 2023

Pathcal launch

Expanded our AI/ML models to cover clinically useful classes of colorectal cancer, such as high-grade dysplasia and adenocarcinoma; evaluated results on internal and external data.

In early 2023, upon defining our product suite and roadmap, we founded Pathcal to guide the disruption of computational pathology.

Who are we?

Our journey

Algorithm development

Large multi-center validation

Cross-over clinical trial

Patent publication

Pathcal launch

Our team

Saeed Hassanpour, Ph.D.

Chairman, Co-founder

Roshan Babu, M.S.

CEO, Co-founder

Arief Suriawinata, M.D.

CMO, Co-founder

Naofumi Tomita, M.S.

CTO, Co-founder